Industry
CBI files charge sheet against RCom, others in ₹3,750 crore LIC fraud case
What is happening to the Indian IT bench? | Explained
UPI volume jumps 27% to touch 145 bn in first half
FPIs turn net sellers, pull out ₹35,860 crore in September
Amazon expands ultra-fast delivery service to more than 120 Indian cities
Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz
The Hindu - Industry·15 Sep 2026
In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
More news in Industry
CBI files charge sheet against RCom, others in ₹3,750 crore LIC fraud caseWhat is happening to the Indian IT bench? | ExplainedUPI volume jumps 27% to touch 145 bn in first halfFPIs turn net sellers, pull out ₹35,860 crore in SeptemberAmazon expands ultra-fast delivery service to more than 120 Indian cities